JP7194683B2 - 化合物、化合物を得るための方法、医薬組成物、化合物の使用、ならびに精神医学的障害および／または睡眠障害を治療するための方法 - Google Patents

化合物、化合物を得るための方法、医薬組成物、化合物の使用、ならびに精神医学的障害および／または睡眠障害を治療するための方法 Download PDF

Info

Publication number
JP7194683B2
JP7194683B2 JP2019542758A JP2019542758A JP7194683B2 JP 7194683 B2 JP7194683 B2 JP 7194683B2 JP 2019542758 A JP2019542758 A JP 2019542758A JP 2019542758 A JP2019542758 A JP 2019542758A JP 7194683 B2 JP7194683 B2 JP 7194683B2
Authority
JP
Japan
Prior art keywords
group
compound
formula
ethyl
benzimidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019542758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537624A (ja
JP2019537624A5 (enExample
Inventor
ルーチ・ベルネック・ギマランイシュ，クリスティアーノ
フェリペ・サネッティ・デ・アゼベード，アティラス
マスカレッロ，アレッサンドラ
ワタナベ・ダ・コスタ，レナータ
フレイレ・トーレス・ルッソ，バウデル
マノッチオ・デ・ソウザ・ルッソ，エリーザ
Original Assignee
アシェ・ラボラトリオス・ファルマセウティクス・エス・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アシェ・ラボラトリオス・ファルマセウティクス・エス・アー filed Critical アシェ・ラボラトリオス・ファルマセウティクス・エス・アー
Publication of JP2019537624A publication Critical patent/JP2019537624A/ja
Publication of JP2019537624A5 publication Critical patent/JP2019537624A5/ja
Application granted granted Critical
Publication of JP7194683B2 publication Critical patent/JP7194683B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019542758A 2016-10-24 2017-10-23 化合物、化合物を得るための方法、医薬組成物、化合物の使用、ならびに精神医学的障害および／または睡眠障害を治療するための方法 Active JP7194683B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BRBR1020160248140 2016-10-24
BR102016024814A BR102016024814A2 (pt) 2016-10-24 2016-10-24 composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
PCT/BR2017/050320 WO2018076090A1 (en) 2016-10-24 2017-10-23 Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders

Publications (3)

Publication Number Publication Date
JP2019537624A JP2019537624A (ja) 2019-12-26
JP2019537624A5 JP2019537624A5 (enExample) 2020-11-26
JP7194683B2 true JP7194683B2 (ja) 2022-12-22

Family

ID=62023150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542758A Active JP7194683B2 (ja) 2016-10-24 2017-10-23 化合物、化合物を得るための方法、医薬組成物、化合物の使用、ならびに精神医学的障害および／または睡眠障害を治療するための方法

Country Status (21)

Country Link
US (2) US10781182B2 (enExample)
EP (2) EP3529234B1 (enExample)
JP (1) JP7194683B2 (enExample)
KR (1) KR102594251B1 (enExample)
CN (2) CN110088092B (enExample)
AR (1) AR109467A1 (enExample)
AU (1) AU2017351756B2 (enExample)
BR (1) BR102016024814A2 (enExample)
CA (1) CA3042040A1 (enExample)
CL (1) CL2019001105A1 (enExample)
CO (1) CO2019004756A2 (enExample)
DK (1) DK3529234T3 (enExample)
EC (1) ECSP19032963A (enExample)
ES (2) ES3013994T3 (enExample)
FI (1) FI3529234T3 (enExample)
MX (1) MX392990B (enExample)
PE (2) PE20191046A1 (enExample)
PT (1) PT3529234T (enExample)
SG (2) SG10202009001TA (enExample)
UY (2) UY40644A (enExample)
WO (1) WO2018076090A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
PT3433256T (pt) 2016-10-24 2019-10-31 Astrazeneca Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]isoquinolina úteis no tratamento do cancro
KR102246668B1 (ko) 2017-01-30 2021-04-29 아스트라제네카 아베 에스트로겐 수용체 조절인자
AR121842A1 (es) * 2020-04-15 2022-07-13 Ache Laboratorios Farmaceuticos Sa Compuesto de benzimidazol para el tratamiento de trastornos metabólicos
PE20221838A1 (es) 2020-04-24 2022-11-29 Astrazeneca Ab Formulaciones farmaceuticas
IL297216A (en) 2020-04-24 2022-12-01 Astrazeneca Ab Dosage regimen for the treatment of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062224A1 (en) 2002-01-17 2003-07-31 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
WO2005080334A1 (ja) 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 新規へテロ環化合物
JP2010503654A (ja) 2006-09-12 2010-02-04 ファイザー・プロダクツ・インク ベンゾイミダゾロン誘導体
JP2010507664A (ja) 2006-10-25 2010-03-11 武田薬品工業株式会社 ベンズイミダゾール化合物
US20110245231A1 (en) 2008-12-15 2011-10-06 Alla Chem, Llc Active substance and pharmaceutical composition for treating alcohol dependence, and a method for obtaining and the use of said active substance

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5260051A (en) 1990-12-17 1993-11-09 Lever Brothers Company, Division Of Conopco, Inc. Compositions comprising phosphate ester compounds containing a beneficial reagent component
FR2674524B1 (fr) 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680366B1 (fr) 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
EP0788795B1 (en) * 1994-06-10 2002-11-13 Nauchno-Issledovatelsky Institut Farmakologii Akademii Meditsinskikh Nauk Pharmacologically active 2-mercaptobenzimidazole derivatives
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
FR2738818B1 (fr) 1995-09-18 1997-12-05 Valentonine Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
WO1998025606A1 (en) 1996-12-10 1998-06-18 Bristol-Myers Squibb Company Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents
CA2334299A1 (en) 1998-06-05 1999-12-09 Pierre Dextraze Heterocyclic cis cyclopropane derivatives as melatonergic agents
AU763963B2 (en) 1999-06-30 2003-08-07 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
ES2264641B1 (es) * 2005-06-17 2008-03-01 Quimica Sintetica, S.A. Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios.
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062224A1 (en) 2002-01-17 2003-07-31 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
WO2005080334A1 (ja) 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 新規へテロ環化合物
JP2010503654A (ja) 2006-09-12 2010-02-04 ファイザー・プロダクツ・インク ベンゾイミダゾロン誘導体
JP2010507664A (ja) 2006-10-25 2010-03-11 武田薬品工業株式会社 ベンズイミダゾール化合物
US20110245231A1 (en) 2008-12-15 2011-10-06 Alla Chem, Llc Active substance and pharmaceutical composition for treating alcohol dependence, and a method for obtaining and the use of said active substance

Also Published As

Publication number Publication date
EP3741760C0 (en) 2024-12-04
ECSP19032963A (es) 2019-05-31
EP3529234A4 (en) 2020-03-11
BR102016024814A2 (pt) 2018-05-08
AU2017351756B2 (en) 2022-01-27
ES3013994T3 (en) 2025-04-16
KR102594251B1 (ko) 2023-10-25
MX392990B (es) 2025-03-24
SG11201903113TA (en) 2019-05-30
EP3741760A1 (en) 2020-11-25
PE20191046A1 (es) 2019-08-06
EP3529234A1 (en) 2019-08-28
UY40644A (es) 2024-02-29
AR109467A1 (es) 2018-12-12
US10781182B2 (en) 2020-09-22
MX2019004782A (es) 2019-10-09
KR20190066023A (ko) 2019-06-12
CN110088092B (zh) 2022-10-04
UY37334A (es) 2018-04-30
US20190270711A1 (en) 2019-09-05
JP2019537624A (ja) 2019-12-26
SG10202009001TA (en) 2020-10-29
ES2970546T3 (es) 2024-05-29
PT3529234T (pt) 2024-02-01
BR112019008197A2 (pt) 2019-07-16
CA3042040A1 (en) 2018-05-03
CN110088092A (zh) 2019-08-02
EP3529234B1 (en) 2023-11-29
CO2019004756A2 (es) 2019-05-21
FI3529234T3 (fi) 2023-12-28
EP3741760B1 (en) 2024-12-04
CL2019001105A1 (es) 2019-09-06
US11091445B2 (en) 2021-08-17
PE20250558A1 (es) 2025-02-24
AU2017351756A1 (en) 2019-05-09
WO2018076090A1 (en) 2018-05-03
CN115181108A (zh) 2022-10-14
DK3529234T3 (da) 2024-02-05
US20200277265A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
JP7194683B2 (ja) 化合物、化合物を得るための方法、医薬組成物、化合物の使用、ならびに精神医学的障害および／または睡眠障害を治療するための方法
JP4139325B2 (ja) ミクロソーム・トリグリセリド・トランスファータンパク質（ｍｔｐ）及び／又はアポリポタンパク質ｂ（ａｐｏｂ）分泌の阻害剤としてのトリアミド置換インドール、ベンゾフラン及びベンゾチオフェン
US8389544B2 (en) Isoquinolone compounds as subtype-selective agonists for melatonin receptors MT1 and MT2
EP3196197A1 (en) Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor
JP2009007344A (ja) グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規１，２，３，４−テトラヒドロキノキサリン誘導体
AU781871B2 (en) PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
EP4378935A1 (en) Benzo [b] selenophene sting regulating agent, preparation method therefor and application thereof
JP2022504650A (ja) シャペロン介在性オートファジー調節剤として有用なベンゾオキサゾールおよび関連化合物
Zhang et al. Recent research advances in ATX inhibitors: An overview of primary literature
CN116354901A (zh) 一种噻唑烷二酮类化合物及其制备方法和应用
US8748608B2 (en) 4-phenylpiperazine derivatives with functionalized linkers as dopamine D3 receptor selective ligands and methods of use
JP2022511269A (ja) シャペロン介在性オートファジー調節剤として有用な化合物
EP3447045B1 (en) 1-(1-hydroxy-2,3-dihydro-1h-inden-5-yl)-urea derivatives and related compounds kcnq 2-5 channel activators for treating dysuria
JP2013525290A (ja) Ｋｓｐ阻害剤としてのオキサゾールおよびチアゾール化合物
HK40081925A (en) Compounds, and preparation process, pharmaceutical composition and use thereof
HK40011198A (en) Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
JP2002534421A (ja) １−フェニル−４−（１−［２−アリール］シクロプロピル）メチルピペラジン：ドーパミン受容体リガンド
HK40011198B (en) Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
BR112019008197B1 (pt) Composto, processo de obtenção do composto, composição farmacêutica e uso do composto
CN101463019B (zh) 含有芳基、芳甲基和哌嗪基的脒类化合物
CN107304180B (zh) 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
KR20240179076A (ko) 신규한 크로멘-벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도
CN102336740A (zh) 一类新型咪唑类化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201016

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221212

R150 Certificate of patent or registration of utility model

Ref document number: 7194683

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250